Read the Latest
Children's Hospital is part of the UPMC family.
Be safe anytime, anywhere.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Ranked #9 Nationally by U.S. News & World Report.
Michael Morowitz, MD, is an associate professor of Surgery and an attending physician in the Division of Pediatric and General Thoracic Surgery. Dr. Morowitz’s research focuses on Necrotizing Enterocolitis (NEC), a mysterious disorder of intestinal inflammation in premature newborn infants. His lab studies the microbiome, the vast collection of microorganisms that cover our bodies, inside and out.
View the transcript for this podcast (PDF)
Brian Martin: This podcast is for informational and educational purposes only and is not to be
considered medical advice for any particular patient. Clinicians must rely on
their own informed clinical judgments when making recommendations for their
patients. Patients in need of medical advice should consult with their personal
From UPMC Children's Hospital of Pittsburgh, welcome to, That's Pediatrics. I'm
Brian Martin. I'm the vice-president of medical affairs here at Children's Hospital
Carolyn Coyne: I'm Carolyn Coyne. I'm a scientist in the Division of Pediatric Infectious Diseases.
Joining us today is Dr. Mike Horowitz, who's an associate professor of surgery at
the University of Pittsburgh School of Medicine. He's Also an attending physician
in the Division of Pediatric General and Thoracic Surgery. His lab is dedicated to
setting changes in the microbiome in critically ill patients. Much of his work is
actually focused on necrotizing enterocolitis in premature infants, but he has
also actually broadened his studies into studies of the microbiome in older
children within the pediatric ICU. Welcome to, That's Pediatrics, Mike.
Mike Morowitz: Thank you for having me.
Carolyn Coyne: I sort of mentioned necrotizing enterocolitis. Why don't you tell us a little bit
Mike Morowitz: Sure. Well, as you mentioned I'm a general pediatric surgeon, and one of the
great unsolved problems in neonatology is a condition called necrotizing
enterocolitis and it's actually one of the few conditions, I would say, that over
the past 50 years has not seen an improvement in outcomes. What it is, is a
disorder of intestinal inflammation in premature newborn infants, typically
within the first month of life. It's characterized by severe intestinal inflammation
that often comes on quite suddenly. Shockingly in 2018, we have very low little
understanding of why some infants and not others develop this problem, which
can be life-threatening.
Carolyn Coyne: How common is it, Mike?
Mike Morowitz: This diagnosis of NEC affects about 7% of premature infants, but the significance
of it actually extends beyond that, because I always say that in NICUs, people
tend to be walking on eggshells sort of afraid that any one infant is going to
develop this problem at any time. What that means in real terms is that a
neonatologist are uncertain how to begin feeding infants, how to and when to
administer antibiotics to infants, because there's been thought for quite a long
time that some of these factors impact whether or not the problem will
develop. Blood transfusions is another one.
My interest in this came about in my training, which finished longer ago than I'd
like to admit, but I was very frustrated by the number of infants that would
develop this problem in a very common situation was that parents would ask
how this problem happened or why it happened, and very commonly would say,
"The baby was doing so well two days ago," and then developed this problem
requiring surgery and that's what led to my interest in the problem.
Carolyn Coyne: Sorry. How soon after birth does something like this presents itself?
Mike Morowitz: The most common time period is three weeks after being born.
Carolyn Coyne: Oh, okay. Is that sort of regardless of when the baby is born in terms of
Mike Morowitz: That's a good question. There is some relationship, and so older infants that are
maybe late preterm tend to have the problem earlier, maybe around 10 to 14
days of life, but the smallest, quote on quote micro premies tend to develop the
problem around three to four weeks of life. But it's always in that first four to six
weeks of life, which is kind of an amazing situation that babies aren't born with
the problem, it didn't start before they were born, and once they go home it
never happens, but it's a peculiar problem to the first few months of life while
they're in the hospital.
Brian Martin: Mike, can you tell us a little bit about briefly some of the surgical management
challenges and then some of the long-term consequences of the situation for
Mike Morowitz: When necrotizing enterocolitis begins, it can begin as a low grade, mild
inflammation of the intestine, and that can be out of the smaller large intestine.
In about two thirds of infants, that can be treated with antibiotics and by
withholding formula or breast milk for a few days, but in one third of patients
surgery is required to remove necrotic or dead intestine that makes children
sick. In that one third of infants requiring surgery, unfortunately, 40 to 50% do
not survive. Of those that do, it's now well-documented that long-term disability
is quite significant, either because intestines had been removed and so they
can't eat later in childhood or because of a neurologic disability. Even though I
am a surgeon, and would like to say that I can cure this problem in the operating
room, I think everybody realizes that we need to figure out how this happens
and how to prevent it before surgery is required.
Brian Martin: Segueing over to your work with a micro bio, is there a hypothesis you
mentioned, or as part of the hypothesis, such that this environment here in the
hospital somehow inhibits or has an effect on the microbiome that's different,
for example, then when we send a very young infant to a home environment?
Mike Morowitz: Well, necrotizing enterocolitis is one of several diseases, and I would include
Crohn's disease, asthma, diabetes. It's one of the diseases in this category
where for 40 or 50 years it had been thought that bacteria or viruses play a role
in the development of the disease. I would say that probably 20 to 30 years ago,
many people gave up on, quote, figuring it out because their studies of the
bacteria that the babies had were hitting a dead end. About 15 years ago, a
really integral advance took place in medical research which involved a 21st
century study of what's referred to as the microbiome. That term is not known
to everybody, but what it refers to is the groups of organisms that we all have
on the body, in the body, and over the past 15 to 20 years, the techniques you
use to study this topic have improved dramatically, just like they have for
studying the human genome itself.
What's been very cool is that during this time, a lot of these diseases where, as I
said, people had sort of given up studying the role of of bacteria and other
organisms, has been reinvigorated. And so when I finished training, it just so
happened to be around the same time that the NIH was launching what they
call the human microbiome project in 2007 to really dive deep into studying
which organisms colonize our bodies when we're healthy and then which do the
same in people that are not healthy. In the case of babies, it's kind of a
fascinating topic, because when babies are born, there's essentially no germs,
but it's important for people to understand that we want bacteria and other
organisms to coat the body, because many of them do really important things.
To get back to your question, we don't really know why, but it is safe to say that
the organisms that you see coating the body of premature infants is very
different from that of full term healthy infants. Why is that? Well, they're
exposed to antibiotics. Because they're born prematurely, the surface of the
intestinal tract on the inside is not as developed in their immune system's not as
developed, and that probably has a role too, so it's multifactorial, but there is
the opportunity to make some advances in I'm distinguishing babies with and
without the problem.
Carolyn Coyne: You brought up sort of an interesting point that that earlier when you were
introducing the problem of NEC was one of the first things that popped into my
head, which is, you think of an infant being born in the NICU, and it being a very
sterile environment, and of course knowing that infants are born sterile, and so
where does that initial microbiome come from? Is it from the mother? Is it from
breast milk? Is it dependent upon mode of delivery? What are the sort of things
that are involved in exposing the infant to the microbiome?
Mike Morowitz: Yeah, the baby's first exposure to microbes, some would call germs, but I don't
like to use that term because it has a bad connotation.
The baby's first exposure to microorganisms is a really, really important time of
life that we're just beginning to understand. The way that a baby's born for
example, has a huge impact. Vaginal delivery is referred to as a natural delivery
and one of the reasons that it is that the mother, during the process of
childbirth, provides her infant with organisms that will help the child, and during
a Cesarean section, that same exposure does not take place. I have two children
that were born by Cesarean section and they're fortunately doing pretty well, so
it's not as though that's a in and of itself a deal breaker to not have that
exposure, but it's one exposure that does adversely impact the microbiome.
Then if you look at antibiotic exposure on top of that, that's probably another
exposure that's better to avoid if possible. Then like you mentioned, breast milk
has been studied quite a bit in the last couple of years and it really does contain
a surprisingly high amount of bacteria and that's no coincidence. It's there to
help the infant, again, to fight infection and to develop the immune system.
Carolyn Coyne: And so, is your research looking at just profiling the microbiome in premature
infants with and without NEC and what have you found?
Mike Morowitz: Right. From our standpoint, the first step is to take what I said was a deep dive
to distinguish babies with and without the problem. I think we're getting to the
point now where we can confidently say that babies that develop the problem
have a slightly altered set of bacteria from infants that don't develop the
disease. And so, the next question will be what to do about it, and that's
something that has motivated a lot of research in my lab, not just in neonates
that are critically ill, but older children as well, because older children in the
pediatric ICU, for example, after a severe trauma or a real bad infection, will
similarly develop massive changes in the colonization of their body by bacteria.
In the last few years, we've been able to show how severe these changes are.
But the next questions are to first determine if they matter in terms of do they
impact outcomes, and assuming that they do, which I think they do, what can
we do about it? There are a number of very inexpensive ways to, quote,
optimize the bacteria on the body and as well there's enormous amount of
interest from the pharmaceutical sector to develop agents either to provide
organisms or to eradicate others. There's quite a bit of interest in manipulating
the microbiome right now.
Brian Martin: Can you speak a little bit, Mike, about your colleagues across the country that
are also doing this work? Are you part of a national ... is there a national
consortium of pediatric surgery that the that's working on NEC? Can you speak
about any inter-institutional work or insights that you've shared with your other
Mike Morowitz: Just in the few years a consortium dedicated to necrotizing enterocolitis has
been initiated and it's really working on a shoe string budget at the moment,
but we are very passionate about the fact that this is a disorder that doesn't
tend to get the exposure that some other equally important conditions do. We
do think that it would benefit children by bringing attention to it ultimately so
that more research can be conducted, some of which is really amazing
molecular 21st century research, but other aspects are really sort of low costs,
common sense interventions such as providing hospitals with support for
lactating mothers so that they can develop the supply of breast milk that's
needed to feed infants, which is really quite an understudied problem in the
setting of preterm birth.
Brian Martin: Yeah. I've had some exposure to the milk as medicine concept and the
importance of building that type of infrastructure at this hospital and other
hospitals to encourage breastfeeding wherever appropriate or possible for atrisk children.
Mike Morowitz: UPMC and Children's Hospital have been very supportive in an initiative to
support the use of donor human milk, as well. That they deserve a lot of credit
in that regard because milk donated from healthy lactating mothers is also
effective in reducing the incidents of this problem and probably has other
understudied benefits as well.
Carolyn Coyne: Yeah, so you mentioned that the sort of bacteria that comprise the microbiome
in infants with NEC, as well as much older and children that are in the ICU, you
see the similar shifts sort of in species. Why is that? Is it treatment related? Is it
sort of the body's response to some sort of trauma, infection as you mentioned
before? What do you think actually causes that?
Mike Morowitz: Yeah, well this is the topic that motivates me the most and it might be a little bit
of a cop out, but it is multifactorial to say that. I think that's one reason why this
particular problem has been harder to study. Specifically what I mean by that is
there are so many reasons why the microbiome becomes altered during critical
illness, ranging from just obvious factors like the fact that care providers are
touching the patient, and you're not used to being a necessarily touched by
these people, and that there will be a transfer of organisms.
Also, you can't necessarily eat. Eating is probably the single most important
determinant of the microbiome, and when you can't eat and you're receiving
intravenous nutrition, that'll be a major change there. Antibiotics, we
mentioned, and as well there are other medications that might be needed to
suppress the immune system, for example, and that will have unintended
consequences on the bacteria. I think it's, as I mentioned, becoming clear that
these changes take place and I think what jazzes me up is thinking about how to
develop treatment plans to rescue the microbiome, so to speak. It's a good
chance that what's effective for person won't be effective for another person.
Carolyn Coyne: It sort of answers a bit of a naive question, of course, that popped into my head
as you were discussing this as well. You know, you see microbes or probiotics on
the shelf in lots of different supplements. Why can't you just give them the
bacteria that they're lacking, let's say, and is that something that you see as a
potential future therapeutic, or what are sort of some of the technical
limitations perhaps if that?
Mike Morowitz: Yeah, so probiotics is one of my least favorite things to talk about, so thank you
Carolyn for bringing that up.
Carolyn Coyne: I assumed as someone whose studied the microbiome, that it might be.
Brian Martin: Thanks for going there, Carolyn.
Mike Morowitz: That's the third rail of microbiome science.
Carolyn Coyne: Exactly, right.
Mike Morowitz: Probiotics is a really interesting topic and what the term means is the
administration of live organisms that have health benefits. A very interesting
fact is that the probiotic industry hasn't been very well or tightly regulated over
the past 100 years or so since the concept was first originated. At the moment,
just about any company can say that they have a probiotic formulation with
health benefits, but it's very, very clear that some do have benefits and some
don't. I think another great challenge for the next 10 years is identifying, really
with some rigor, which organisms, what dose to use, again, whether one
formulation of probiotics might be helpful in one group of people but another
would be better for another.
It's somewhat complicated, because when you ask somebody to swallow a pill
with some probiotics, much of it may not even survive the stomach, which is a
harsh, acidic environment. It really needs to be studied better. I will say that the
safety profile of probiotics is quite good, very, very few adverse events in
published studies, but at least in children's hospitals and especially in neonatal
ICUs in the United States, there has been great reluctance because of potential
safety problems to administer live organisms to a very fragile infant. But in
other parts of the world, in Asia and Europe, a number of places have studied
large studies of probiotics in newborns and the results have been mixed.
Brian Martin: One other question about the, the diet-based interventions, how receptive have
your ICU colleagues in the pediatric ICU world, been to these to your
investigation and changing conversation in regards to nutritional management?
You know, longstanding probably as your role as a pediatric surgeon, the
knowledge about nutrition and wound healing, but specifically in the concept of
evolving, positively evolving a microbiome. Can you tell us a little bit about how
interdisciplinary work is there?
Mike Morowitz: It's going really well, but it's definitely an in, in its early stages. This is something
else that I'm trying to draw attention to and specifically, I mean, I happen to
know that both of you host enjoy eating nice food and trying interesting types
of meals. One thing that has bothered me for quite a long time is that when we
have patients in the hospital that arguably are in the greatest need for a wellbalanced nutritious meal, the options for providing them nutrition are
Typically, various hospitals have had contracts with companies that provide
formulas for nutrition, and those contracts have been in place for decades, and
those formulas have done a lot of good for people of all ages, but it's my feeling
that it's time to modernize our approach to nutrition. Specifically, I think that it's
becoming increasingly possible to provide real food, whether blenderized or
pureed, to patients that can't eat. Now, this doesn't necessarily apply to
newborn infants, of course, but but to older people in the hospital. That's
something that we'd like to develop over the next couple of years. That too has
a major microbiome angle, because when you provide a real foods such as
plants and vegetables, you promote the growth of the body's own probiotics,
for example, without actually administering exogenous organisms.
Carolyn Coyne: Well, this was really interesting, Mike. Thank you for joining us.
Mike Morowitz: Thanks for having me.
Brian Martin: Thanks very much for your time, Mike.
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
UPMC Children’s Hospital of Pittsburgh
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Support the hospital by making a donation online, joining our Heroes in Healing monthly donor program, or visiting our site to learn about the other ways you can give back.